Want to see AU:CBL full AI Analyst Report?
CBL Stock Chart & Stats
AU$0.06
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.06
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.10
Previous CloseN/A
Volume65.91K
Average Volume (3M)764.47K
Market Cap
AU$31.50M
Enterprise ValueAU$29.03
Total Cash (Recent Filing)AU$2.08M
Total Debt (Recent Filing)AU$618.92K
Price to Earnings (P/E)―
Beta-0.18
Next Earnings
Feb 24, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding543,088,700
10 Day Avg. Volume957,131
30 Day Avg. Volume764,467
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)4.35
Price to Sales (P/S)5.76
P/FCF Ratio-4.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized Assistive TechnologyThe company operates in a specialized assistive-technology niche addressing critical communication and device-access needs. Its EMG and human-machine interface focus may support differentiated products and lasting relevance for underserved users.
Low Financial LeverageModest leverage limits interest and refinancing pressure, giving the company more balance-sheet flexibility than a highly indebted business. This provides some capacity to fund operations or strategic initiatives while restructuring performance.
2026 FCF ImprovementThe positive year-on-year movement in 2026 free cash flow suggests some operational improvement, even though cash generation remains inadequate. If sustained, this trend could help reduce the pace of external funding reliance.
Bears Say
Revenue ContractionThe recent revenue decline indicates weakening demand, execution, or product-market traction after limited prior growth. Sustained contraction would reduce operating leverage, constrain investment capacity, and make a path to profitability more difficult.
Persistent UnprofitabilityRecurring substantial losses show that the current business model has not yet achieved economic sustainability. Without a credible improvement in pricing, volume, or costs, ongoing losses may continue eroding equity and require additional capital.
Negative Cash GenerationPersistent negative operating and free cash flow means operations are not self-funding and remain dependent on external capital. This limits strategic flexibility and creates dilution or liquidity risk if losses and cash burn continue.
Control Bionics Ltd. News
CBL FAQ
What was Control Bionics Ltd.’s price range in the past 12 months?
Control Bionics Ltd. lowest share price was AU$0.03 and its highest was AU$0.10 in the past 12 months.
What is Control Bionics Ltd.’s market cap?
Control Bionics Ltd.’s market cap is AU$31.50M.
When is Control Bionics Ltd.’s upcoming earnings report date?
Control Bionics Ltd.’s upcoming earnings report date is Feb 24, 2027 which is in 172 days.
How were Control Bionics Ltd.’s earnings last quarter?
Control Bionics Ltd. released its earnings results on Aug 27, 2026. The company reported -AU$0.009 earnings per share for the quarter.
Is Control Bionics Ltd. overvalued?
According to Wall Street analysts Control Bionics Ltd.’s price is currently Overvalued.
Does Control Bionics Ltd. pay dividends?
Control Bionics Ltd. does not currently pay dividends.
What is Control Bionics Ltd.’s EPS estimate?
Control Bionics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Control Bionics Ltd. have?
Control Bionics Ltd. has 543,088,700 shares outstanding.
What happened to Control Bionics Ltd.’s price movement after its last earnings report?
Control Bionics Ltd. reported an EPS of -AU$0.009 in its last earnings report. Following the earnings report the stock price went down -3.333%.
Which hedge fund is a major shareholder of Control Bionics Ltd.?
Currently, no hedge funds are holding shares in AU:CBL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Control Bionics Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:CBL Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$347.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
63.15%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.89%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Control Bionics Ltd.
Operating in Australia and North America, Control Bionics Limited and its subsidiaries specialize in the innovation, development, and market introduction of sophisticated assistive communication technologies. The company's offerings include the NeuroNode Trilogy and NeuroNode3 systems, which empower individuals facing speech and mobility challenges to control computers for speech generation, electronic correspondence, leisure activities, and remote operation of other devices. Control Bionics also provides Cosmos Connect, a versatile interface capable of managing diverse equipment like wheelchairs, robotic dining aids, and gaming consoles. Additionally, they offer Uno Touch, a dedicated speech-generating device, alongside various other sensors for a broad spectrum of uses. Founded in 2005, the entity was initially named Control Bionics Holdings Pty Limited before rebranding as Control Bionics Limited in September 2020. The company's base of operations is situated in Camberwell, Australia.
Technical Analysis
Nova Eye Medical
―
Cochlear
―
Compumedics Limited
―
Neurotech International
―
EMvision Medical Devices Ltd.
―